Home > Insider Trading > Filing (0001209191-19-026033)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1423824	Alder Biopharmaceuticals Inc	ALDR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1664928	B James Bucher	11804 North Creek Parkway South Bothell WA 98011	Evp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-23	7,810	$0.00	11,706	No	4	A	Direct
Common Stock	Disposition	2019-04-25	1,897	$13.85	9,809	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 23,429 shares of Issuer's Common Stock (the "RSU"). Up to 7,810 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the "FDA") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the "FDA Filing Milestone") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 7,810 shares subject to the RSU.
Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.